INTRODUCTION
============

3-hydroxy-3-methylgutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are cholesterol-lowering drugs which work by blocking the rate-limiting step in the cholesterol synthesis pathway ([Fig. 1](#f1-jlm-04-71){ref-type="fig"}). Stains are the most frequently and widely used medication in the treatment of cardiovascular disease, diabetes, and cancer to reduce cholesterol levels (*e.g.*, LDL-cholesterol) by inhibiting the formation of mevalonate (a precursor to cholesterol), ubiquinone (coenzyme Q), and other compounds \[[@b1-jlm-04-71],[@b2-jlm-04-71]\]. Although statins have a number of beneficial effects including a lipid-lowering effect, improved endothelial function, anti-inflammation, and insulin sensitivity \[[@b1-jlm-04-71],[@b3-jlm-04-71]\], statins, particularly lipophilic statins (*e.g.*, simvastatin, atorvastatin, cerivastatin, and lovastatin), also cause adverse side effects in skeletal muscle ranging from mild to moderate muscle fatigue, weakness, and pain to fatal rhabdomyolysis \[[@b4-jlm-04-71]--[@b6-jlm-04-71]\]. In fact, considering that the occurrence of less adverse side effects is not reported, the incidence of statin-induced myopathy may be 5--10%, and concerns about the safety of statins on skeletal muscle are expected to increase \[[@b7-jlm-04-71]\]. However, the underlying mechanisms by which statins induce skeletal muscle side effects have not been clearly determined. Therefore, this review primarily focuses on statin-induced myopathy and the potential mechanisms of statin-associated myopathy. In addition, this review provides an overview of the role of exercise in stain-induced myopathy.

EFFECTS OF STATINS ON SKELETAL MYOPATHY
=======================================

Statins, widely prescribed cholesterol-lowering drugs for the treatment of dyslipidemia and cardiovascular disease, are associated with skeletal muscle-related complaints or myopathies. Apoptosis is programmed cell death that is highly regulated and executed via the activation of caspase dependent or independent signaling. In general, apoptosis plays an important role in governing development, growth, and repair in cells \[[@b8-jlm-04-71]\]. However, excessive apoptosis may be associated with dysfunction, disease, and myopathy in skeletal muscle. It has been reported that statin treatment can induce apoptosis in skeletal muscle in both human \[[@b9-jlm-04-71]--[@b12-jlm-04-71]\] and rodent \[[@b13-jlm-04-71]--[@b16-jlm-04-71]\] models. For example, simvastatin treatment (5 *μ*M) during 48 hours increased protein levels of proapoptotic protein Bax and apoptosis marker TUNEL-positive nuclei in primary human skeletal muscle cells \[[@b12-jlm-04-71]\]. Furthermore, Kobayashi et al. \[[@b11-jlm-04-71]\] showed that cerivastatin treatment (100 *μ*M) during 24--72 hours elevated apoptosis in rhabdomyosarcoma cells from human subjects.

Mitochondria play a central role in regulating homeostasis as well as inducing apoptosis in skeletal muscle. Therefore, mitochondrial dysfunction is associated with the increase in the susceptibility to apoptosis and oxidative stress in skeletal muscle. Previous studies showed that statins might impair mitochondrial function in the skeletal muscles of humans \[[@b17-jlm-04-71]--[@b23-jlm-04-71]\] and animals \[[@b15-jlm-04-71],[@b24-jlm-04-71]\], leading to myopathy. For example, patients with hypercholesterolemia taking simvastatin (80 mg/day) for 8 weeks displayed a decrease in mitochondrial respiratory chain enzyme and citrate synthase activities \[[@b20-jlm-04-71]\]. Stains also inhibit the synthesis of ubiquinone (coenzyme Q10), a major electron carrier in the mitochondrial respiratory chain \[[@b5-jlm-04-71],[@b17-jlm-04-71]\]. However, statin treatment does not appear to consistently affect mitochondrial function in the whole body. Chung et al. \[[@b25-jlm-04-71]\] showed that fat oxidation and respiratory exchange ratio (RER) did not change in patients with hypercholesterolemia taking atorvastatin (40 mg/day) for 8 weeks. [Table 1](#t1-jlm-04-71){ref-type="table"} summarizes the effects of statins on the whole body and skeletal myopathy.

POTENTIAL MECHANISMS OF STATIN-INDUCED MYOPATHY
===============================================

Although numerous studies on statin-associated myopathy have been reported in animals and humans, the molecular mechanisms of statin-induced myopathy have not been completely elucidated. A variety of hypotheses regarding potential mechanisms of statin-induced myopathy have been proposed to gain insight into myopathy in skeletal muscle, including (a) deficiency of ubiquinone, (b) reactive oxygen species (ROS) production, and (c) induction of apoptosis.

Ubiquinone is located in the mitochondrial respiratory chain, where it plays an essential role in transferring electrons from complex I and II to complex III associated with oxidative phosphorylation and energy production \[[@b27-jlm-04-71]\]. In addition, ubiquinone acts as a potent antioxidant in the inner mitochondrial membrane by scavenging free radicals \[[@b28-jlm-04-71]\]. However, it has been shown that statins reduced levels of ubiquinone in muscle and blood ([Fig. 2](#f2-jlm-04-71){ref-type="fig"}). The rationale of statin-induced decrease in ubiquinone is the fact that statins can inhibit the biosynthesis of ubiquinone as well as cholesterol in the cholesterol synthesis pathway as shown in [Fig. 1](#f1-jlm-04-71){ref-type="fig"}. For example, blood and muscle concentrations of ubiquinone were decreased after short- and long-term treatment with statins \[[@b20-jlm-04-71],[@b29-jlm-04-71]\], which suggests that deficiency of ubiquinone in mitochondria may impair cellular respiration resulting in skeletal myopathy and that supplementation with ubiquinone may be an appropriate therapy to counteract adverse side effects of statin treatment.

Impaired mitochondrial function is involved in the production of oxidative stress in cells. Most oxidative stress, such as ROS, is generated in the mitochondria. In particular, superoxide (O~2~^ㆍ−^) free radicals are generated from complex I (mainly) and complex III in the electron transport system and changed to hydrogen peroxide (H~2~O~2~). It has been recently reported that statin treatment increased oxidative stress in human skeletal muscle cells \[[@b12-jlm-04-71]\] and fibers \[[@b23-jlm-04-71]\] ([Fig. 3](#f3-jlm-04-71){ref-type="fig"}). For example, we recently found that simvastatin treatment induced mitochondrial oxidative stress as indicated by increases in O~2~^ㆍ−^ and H~2~O~2~ production as well as impaired oxygen consumption supported by complex I substrates (glutamate + malate) \[[@b12-jlm-04-71]\].

In addition, it has been suggested that statin-induced myopathy is associated with apoptosis in skeletal muscle \[[@b5-jlm-04-71],[@b9-jlm-04-71],[@b12-jlm-04-71],[@b30-jlm-04-71]\]. As mentioned above, statins induce apoptosis in skeletal muscle, which may be an essential factor causing myopathy experienced by patients taking stains. In general, apoptosis is induced through three major apoptotic signaling pathways: the (a) mitochondrial-driven pathway, (b) cytokines/Fas-driven pathway, and (c) endoplasmic reticulum (ER)/Ca^2+^-driven pathway \[[@b31-jlm-04-71]\]. However, statin-induced apoptosis in skeletal muscle may be mitochondrial-mediated as indicated by an increase in Bax, release of cytochrome c, active caspase-9, and caspase-3 by statin treatment \[[@b12-jlm-04-71],[@b30-jlm-04-71]\]. In particular, the increase in ROS (*e.g.*, O~2~^ㆍ−^ and H~2~O~2~) generation with statin treatment may play an important role in opening the mitochondrial permeability transition pore (mPTP), which results in caspase dependent (*e.g.*, cytochrome c and caspase-9) or independent (*e.g.*, apoptosis inducing factor \[AIF\] and EndoG) apoptosis in skeletal muscle ([Fig. 3](#f3-jlm-04-71){ref-type="fig"}), suggesting that statin-induced oxidative stress triggers mitochondrial-mediated apoptosis. For example, Kwak et al. \[[@b12-jlm-04-71]\] demonstrated that simvastatin treatment induced apoptosis as well as oxidative stress in differentiated skeletal muscle cells.

ROLE OF EXERCISE IN STAIN-INDUCED MYOPATHY: FRIEND OR FOE?
==========================================================

Exercise is regarded as one of the most cost effective ways to prevent metabolic and cardiovascular diseases and is recommended to patients as a lifestyle intervention to supplement drug therapy. However, the benefit/risk of exercise with statin therapy has not been thoroughly investigated. To date, the effects of exercise frequency, intensity, time or type on the risk of statin-induced myopathy have not been well studied. Most studies of the interactions of exercise and statin therapy include an acute/single exercise and indirect measures of muscle damage (*i.e.*, blood creatine kinase \[CK\] levels). In contrast to statin-induced myopathy, chronic exercise training has the potential to counteract statin-induced side effects in skeletal muscle. For example, endurance exercise training increases mitochondrial biogenesis and mitochondrial respiration, and decreases oxidative stress and apoptosis in skeletal muscle \[[@b32-jlm-04-71]\].

However, previous studies have shown inconsistent findings regarding the effects of exercise on statin-induced myopathy. While some studies reported that exercise seemed to increase the risk of statin-induced myopathy \[[@b33-jlm-04-71]--[@b37-jlm-04-71]\], others suggested that exercise did not affect statin-induced myopathy \[[@b33-jlm-04-71],[@b38-jlm-04-71]--[@b42-jlm-04-71]\]. For example, 12 weeks of aerobic exercise training in combination with simvastatin (40 mg/day) decreased cardiorespiratory fitness and muscle citrate synthase activity in obese subjects \[[@b36-jlm-04-71]\]. In addition, 2 weeks of treadmill exercise increased muscle damage in rats taking cerivastatin (0.5--1.0 mg/kg/day) for 2 weeks \[[@b37-jlm-04-71]\]. In contrast, 10 weeks of endurance and resistance exercise training did not affect serum CK in hypercholesterolemic patients taking rosuvastatin (10 mg/day) for 20 weeks \[[@b40-jlm-04-71]\]. Furthermore, Meador and Huey \[[@b42-jlm-04-71]\] showed that 4 weeks of wheel running exercise with cerivastatin treatment (1 mg/kg/day) for 2 weeks prevented statin-associated force loss and increased fatigability in mice, suggesting that exercise prior to statin treatment can protect against statin-induced muscle dysfunction. [Table 2](#t2-jlm-04-71){ref-type="table"} shows a summary of studies examining the effects of exercise on statin-induced myopathy in human and animal models.

CONCLUSIONS
===========

Statins are common cholesterol-lowering drugs for treating cardiovascular disease. However, adverse side effects of statins include skeletal muscle myopathy. Although the mechanisms of statin-induced skeletal myopathy have not been determined, the mechanisms may be associated with ubiquinone deficiency, oxidative stress, and apoptosis. However, the underlying molecular and cellular mechanism by which statins affect mitochondrial function and apoptosis in skeletal muscle remains unknown. Furthermore, it is not clear whether exercise exacerbates statin-associated myopathy in skeletal muscle. Therefore, further studies of patients taking statins with different kinds of exercise are warranted to develop new strategies for statin-associated mitochondrial dysfunction and apoptosis leading to skeletal myopathy.
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###### 

Effects of statins on whole body and skeletal myopathy

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Subject or animal                       Sex      Types of statins (doses)       Treatment          Duration        Tissues                                            Results                                    References
  --------------------------------------- -------- ------------------------------ ------------------ --------------- -------------------------------------------------- ------------------------------------------ ---------------------------------------------
  Patients with hypercholesterolemia      Both     Simvastatin\                   Oral intake        8 weeks         Serum                                              ↓ Ubiquinone\                              Pinieux et al., 1996 \[[@b17-jlm-04-71]\]
                                                   Pravastatin\                                                                                                         ↑ Lactate/pyruvate ratio                   
                                                   Fluvastatin                                                                                                                                                     

  Patients with hypercholesterolemia      Both     Simvastatin (80 mg/day)\       Oral intake        2--4 years      Muscle biopsy                                      ↓ Muscle strength\                         Phillips et al., 2002 \[[@b18-jlm-04-71]\]
                                                   Lovastatin (40 mg/day)\                                                                                              ↓ Cytochrome oxidase activity              
                                                   Atorvastatin (20 mg/day)                                                                                                                                        

  Healthy subjects                        \-       Simvastatin (30 *μ*M)          Cell culture       24 hours        Primary skeletal muscle cells from muscle biopsy   ↑Apoptosis                                 Sacher et al., 2005 \[[@b9-jlm-04-71]\]

  Healthy subjects                        Male     Simvastatin (200 *μ*M)         Fiber incubation   Acute           Muscle biopsy (quadriceps)                         ↑ Mitochondrial membrane depolarization\   Sirvent et al., 2005 \[[@b19-jlm-04-71]\]
                                                                                                                                                                        ↑ Cytoplasmic Ca^2+^                       

  Patients with hypercholesterolemia      Both     Simvastatin (80 mg/day)        Oral intake        8 weeks         Muscle biopsy (quadriceps femoris)                 ↓ Respiratory chain enzyme\                Paiva et al., 2005 \[[@b20-jlm-04-71]\]
                                                                                                                                                                        ↓ Citrate synthase activity                

  Patients with heart disease             \-       Simvastatin (5 *μ*M)           Cell culture       96 hours        Cardiac myocytes                                   ↓ Mcl-1(inhibitor of apoptosis)\           Demyanets et al., 2006 \[[@b10-jlm-04-71]\]
                                                                                                                                                                        ↔ Bax\                                     
                                                                                                                                                                        ↑ DNA fragmentation                        

  Healthy subjects                        \-       Cerivastatin (100 *μ*M)        Cell culture       24--72 hours    Rhabdomyosarcoma cells                             ↑ Apoptosis                                Kobayashi et al., 2007 \[[@b11-jlm-04-71]\]

  Patients with hypercholesterolemia      Both     Simvastatin (80 mg/day)        Oral intake        8 weeks         Muscle biopsy (quadriceps)                         ↓ Mitochondrial DNA\                       Schick et al., 2007 \[[@b21-jlm-04-71]\]
                                                                                                                                                                        ↓ LDL                                      

  Patients with hypercholesterolemia      Female   Atorvastatin (40 mg/day)       Oral intake        8 weeks         \- Whole body\                                     ↔ RER & anaerobic threshold\               Chung et al., 2008 \[[@b25-jlm-04-71]\]
                                                                                                                     - Plasma                                           ↔ Fat oxidation                            

  Patients with hypercholesterolemia      Both     Simvastatin (10--80 mg/day)\   Oral intake        4 months        Muscle biopsy (vastus lateralis)                   ↓ Oxidative phosphorylation                Hubal et al., 2011 \[[@b22-jlm-04-71]\]
                                                   Atorvastatin (10--80 mg/day)                                                                                                                                    

  Patients with statin-induced myopathy   Both     Simvastatin (20 mg/day)\       Oral intake        24--48 months   Muscle biopsy (deltoid)                            ↑ ROS\                                     Bouitbir et al., 2012 \[[@b23-jlm-04-71]\]
                                                   Atorvastatin (20 mg/day)                                                                                             ↓ mRNA of SOD1,2                           

  Healthy subjects                        Male     Simvastatin (5 *μ*M)           Cell culture       48 hours        Primary skeletal muscle cells from muscle biopsy   ↓ O~2~ consumption\                        Kwak et al., 2012 \[[@b12-jlm-04-71]\]
                                                                                                                                                                        ↑ O^ㆍ−^~2~ & H~2~O~2~\                    
                                                                                                                                                                        ↑ Apoptosis                                

  Rats                                    Male     Atorvastatin (100 *µ*M)        Cell culture       24 hours        Vascular smooth muscle cells                       ↑ Apoptosis                                Guijarro et al., 1998 \[[@b13-jlm-04-71]\]

  Rats & Humans                           \-       Cerivastatin (50, 100 nM)      Cell culture       24 hours        \- L-6 cells\                                      ↑ Apoptosis                                Johnson et al., 2004 \[[@b14-jlm-04-71]\]
                                                                                                                     - Human (fetal thigh) myotubes                                                                

  Rats                                    Male     Fluvastatin (20 mg/kg/day)\    Oral intake        2 months        Muscle biopsy (EDL, TA)                            ↑ Myoglobinemia                            Pierno et al., 2006 \[[@b26-jlm-04-71]\]
                                                   Atorvastatin (10 mg/kg/day)                                                                                                                                     

  Mice                                    Both     Lovastatin (100 mg/kg/day)     Oral intake        15 days         Mitochondria from muscle and liver                 ↑ Mitochondrial permeability transition    Velho et al., 2006 \[[@b24-jlm-04-71]\]

  Rats                                    \-       Cerivastatin (100 *µ*M)\       Cell culture       24 hours        L-6 cells                                          ↑ Cell death (apoptosis)\                  Kaufmann et al., 2006 \[[@b15-jlm-04-71]\]
                                                   Fluvastatin (100 *µ*M)\                                                                                              ↓ Mitochondrial membrane potential\        
                                                   Atorvastatin (100 *µ*M)\                                                                                             ↓ O~2~ consumption & beta-oxidation        
                                                   Simvastatin (100 *µ*M)                                                                                                                                          

  Rats                                    Female   Simvastatin (88 mg/kg/day)     Oral intake        12 days         Muscle biopsy (biceps femoris)                     ↑ Necrosis\                                Mallinson et al., 2012 \[[@b16-jlm-04-71]\]
                                                                                                                                                                        ↑ PDK4 & MAFbx                             
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Effects of exercise on statin-induced myopathy

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Subject or animal                    Sex      Types of exercise (Duration)                   Types of statins (doses)            Duration of statin treatment   Tissues                             Results                                                   References
  ------------------------------------ -------- ---------------------------------------------- ----------------------------------- ------------------------------ ----------------------------------- --------------------------------------------------------- ---------------------------------------------
  Healthy subjects                     Male     Acute eccentric treadmill exercise (1 hour)    Lovastatin (40 mg/day)              30 days                        Serum                               ↔ CK                                                      Reust et al., 1991 \[[@b38-jlm-04-71]\]

  Healthy subjects                     Both     Acute maximal treadmill exercise               Lovastatin (20 mg/day)              4 weeks                        Serum                               ↔ CK                                                      Thompson et al., 1991 \[[@b39-jlm-04-71]\]

  Healthy subjects                     Male     -Acute downhill treadmill walking (45 min)\    Lovastatin (40 mg/day)              5 weeks                        Serum                               \- Downhill treadmill: ↑ CK\                              Thompson et al., 1997 \[[@b33-jlm-04-71]\]
                                                -Acute biceps curl exercise (10 RM, 4 sets)                                                                                                           - Biceps exercise: ↔ CK                                   

  Healthy subjects                     Male     Acute eccentric contractions (30 min)          Atorvastatin (80 mg/day)            4 weeks                        Muscle biopsy (vastus lateralis)    ↑ Ubiquitin proteasome pathway & catabolism               Urso et al., 2005 \[[@b34-jlm-04-71]\]

  Patients with hypercholesterolemia   Both     Endurance and resistance exercise (10 weeks)   Rosuvastatin (10 mg/day)            20 weeks                       Serum                               ↔ CK                                                      Coen et al., 2009 \[[@b40-jlm-04-71]\]

  Athletes with hypercholesterolemia   Both     Acute marathon                                 All statins (various doses)         6 months                       Plasma                              ↑ Statin-related muscle injury (CK)                       Parker et al., 2012 \[[@b35-jlm-04-71]\]

  A healthy subject                    Male     Acute aerobic exercise (1 h 42 min)            Simvastatin (10 mg/day)             6 months                       Blood                               ↔ Lipoprotein & white blood cell concentrations           Semple, 2012 \[[@b41-jlm-04-71]\]

  Obese subjects                       Both     Aerobic exercise (12 weeks)                    Simvastatin (40 mg/day)             12 weeks                       -Whole body\                        ↓ Cardiorespiratory fitness\                              Mikus et al., 2013 \[[@b36-jlm-04-71]\]
                                                                                                                                                                  -Muscle biopsy (vastus lateralis)   ↓ Muscle citrate synthase activity                        

  Rats                                 Female   Treadmill exercise (2 weeks)                   Cerivastatin (0.5, 1.0 mg/kg/day)   2 weeks                        Muscles                             ↑ Muscle damage                                           Seachrist et al., 2005 \[[@b37-jlm-04-71]\]

  Mice                                 Male     Wheel running (4 weeks)                        Cerivastatin (1 mg/kg/day)          2 weeks                        Whole body                          ↓ Statin-associated force loss & increased fatigability   Meandor and Huey, 2011 \[[@b42-jlm-04-71]\]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
